Evofosfamide . The results from MAESTRO, a phase III trial examining evofosfamide in advanced pancreas cancer patients, show the treatment offers little-to-no advantage to both patients with pancreatic cancer and soft tissue sarcoma (STS) were presented at an oral session at the ASCO Gastrointestinal Cancers Symposium.

John Otrompke

Published Online: 5:50 PM, Wed January 27, 2016

"Patients on the control arm could crossover to get evofosfamide once they had progressed. This confounded the survival results in the phase II (ie, the control arm performed better with the patients who subsequently got evofosfamide). There was no crossover in the Phase III."

- Laura Hansen, PhD

...